查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
放射性配體治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按適應症、產品、生物標記、終端用戶、公司和地區分類
市場調查報告書
商品編碼
1289656

放射性配體治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按適應症、產品、生物標記、終端用戶、公司和地區分類

Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication, By Product, By Biomarker, By End User, By Company, and By Region
出版日期: | 出版商: TechSci Research | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在2023-2027年的預測期內，全球放射性配體治療市場預計將出現令人矚目的成長。主要因素，包括各種類型癌症發病率的上升和對阿爾法放射免疫療法認知的提高，正在推動該市場的成長。放射性免疫療法是一種治療某些類型癌症的先進方法。它向目標癌細胞提供輻射，而對健康細胞的影響可以忽略不計。這種療法為那些沒有充分治療選擇的癌症患者提供了改善生命的治療。支持市場成長的其他因素有：世界人口成長、龐大的患者群體、技術進步帶來的產品創新和開發的上升、政府投資的增加、醫療領域放射性同位素的增加、人均醫療支出的上升、合併和戰略收購數量的增加，以及大量的臨床試驗。

各種類型癌症的發病率上升

癌症是全世界的主要死因。各種類型的癌症，特別是前列腺癌和神經內分泌腫瘤的發病率不斷上升，正在推動市場的成長。根據國際癌症研究機構（IARC）的數據，2018年，全球約有1700萬新的癌症病例和950萬癌症相關的死亡病例。前列腺癌和神經內分泌腫瘤是最常見的癌症，特別是在美國男性。根據美國癌症協會的數據，2019年，在美國發現了大約174,650個前列腺癌新病例。由於患癌症的病人數量增加，對放射性配體療法的需求激增，推動了市場的成長。

對阿爾法放射免疫療法認知的提高和研發活動的增加

阿爾法放射免疫療法是一種有針對性的抗腫瘤療法，能夠提供成功的治療。因此，人們和醫生對阿爾法放射免疫療法的認知的提高正在推動市場的成長。此外，用於治療各種癌症類型的放射性配體療法的研究和開發的增加，正在促進全球放射性配體療法市場的發展。由於不斷的研究和開發活動，出現了一些新的方法，如Lutetium 177、前列腺特異性膜抗原（PSMA）等，用於治療癌症。例如，POINT Biopharma Global Inc.正計劃以PNT2003藥物進入放射性配體治療市場，該藥物目前正處於臨床試驗的最後階段。

政府不斷增加的投資和上升的計劃

政府為減少癌症負擔而增加的投資和各種計劃正在推動市場的成長。例如，在2021年，歐盟委員會推出了歐洲戰勝癌症計劃，旨在提供癌症服務，重點是疾病預防和早期診斷。後來，在2022年，歐洲政府打算為癌症研究和護理投入超過42億美元。

可用的定製服務

利用給定的市場數據，TechSci Research根據公司的具體需求提供定製服務。該報告可提供以下定製選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球放射性配體治療市場的影響

第五章：客戶的聲音

第六章：臨床試驗分析

第七章：全球放射性配體治療市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按適應症（前列腺癌、神經內分泌腫瘤、其他）分類
    • 按產品（Lutathera, Zytiga, Xtandi, Xofigo）分類
    • 按生物標記（前列腺特異性膜抗原、Ki 67表達和分級、細胞色素P450 17A1抑製劑）分類
    • 按終端用戶（生物技術和製藥公司、學術和研究機構、其他）分類
    • 按地區
    • 按公司分類(2021年)
  • 市場地圖

第8章：北美放射配體治療市場前景

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率與預測
    • 按適應症分類
    • 按產品分類
    • 按生物標記分類
    • 按終端用戶
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 美國
    • 墨西哥

第九章：歐洲放射性配體治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按適應症分類
    • 按產品分類
    • 按生物標記分類
    • 按終端用戶
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第十章：亞太地區放射性配體治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按適應症分類
    • 按產品分類
    • 按生物標記分類
    • 按終端用戶
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第十一章：南美放射配體治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按適應症分類
    • 按產品分類
    • 按生物標記分類
    • 按終端用戶
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第十二章：中東和非洲放射配體治療市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按適應症分類
    • 按產品分類
    • 按生物標記分類
    • 按終端用戶
    • 按國家分類
  • MEA: 國家分析
    • 南非放射性配體治療
    • 沙烏地阿拉伯放射性配體治療
    • 阿拉伯聯合大公國放射性配體治療

第十三章：市場動態

  • 驅動力
  • 挑戰

第十四章：市場趨勢與發展

第十五章：競爭格局(包括SWOT分析)

  • 諾華國際公司（Novartis International, AG
  • 強生公司
  • 輝瑞公司（Pfizer）。
  • Amneal Pharmaceuticals LLC.
  • POINT Biopharma Global Inc
  • Fusion Pharmaceuticals Inc.
  • Clovis Oncology, Inc.
  • Telix Pharmaceuticals Limited
  • Lantheus Holdings, Inc.
  • Progenics Pharmaceuticals
  • 拜耳公司

第16章：戰略建議

簡介目錄
Product Code: 13045

The global radioligand therapy market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of various types of cancers and increasing awareness of alpha radioimmunotherapy, are propelling the growth of the market. Radioligand therapy is an advanced approach to treat certain kinds of cancer. It provides radiation to targeted cancer cells, with a negligible effect on healthy cells. This therapy provides life-enhancing treatment for patients with cancer who have inadequate therapeutic options. The other factors supporting the market's growth are a growing world population, large patient pool, rising product innovation and development due to technological advancements, increasing government investments, increasing radioisotopes in healthcare, rising per capita healthcare expenditure, growing number of mergers and strategic acquisitions, and a large number of clinical trials.

Rising Incidence of Various types of Cancers

Cancer is a leading cause of death across the world. The growing prevalence of various types of cancers, especially prostate cancer and neuroendocrine tumors, is bolstering the growth of the market. According to the International Agency for Research on Cancer (IARC), in 2018, there were approximately 17.0 million new cancer cases and 9.5 million cancer-related deaths across the world. Prostate cancer and neuroendocrine tumors are the most common cancer, especially in American men. As per the American Cancer Society, in 2019, around 174,650 new cases of prostate cancer were detected in the U.S. Owing to the rise in the number of patients suffering from cancer, the surge in demand for radioligand therapy is driving the growth of the market.

Increased Awareness of Alpha Radioimmunotherapy and Rise in R&D Activities

Alpha Radioimmunotherapy is a targeted anti-tumor therapy that provides successful treatments. Therefore, the rise in awareness among people and physicians regarding alpha-radioimmunotherapy is bolstering the growth of the market. In addition, the rise in research & development of radioligand therapy to treat a wide range of cancer types is augmenting the global radioligand therapy market, globally. The advent of novel methods, such as lutetium 177, prostate-specific membrane antigen (PSMA), and others, for the treatment of cancer is due to continuous research and development activities. For instance, POINT Biopharma Global Inc. is planning to enter the market for radioligand therapy with the PNT2003 drug, which is presently in the last phases of clinical trials.

Increasing Investments and rising Initiatives by the Government

The rise in investments and various initiatives by governments to reduce the cancer burden is propelling the growth of the market. For instance, in 2021, the European Commission launched Europe's Beating Cancer Plan, which aims to offer cancer services with a focus on disease prevention and early diagnosis. Later, in 2022, the European government intended to pour over $4.2 billion into cancer research and care.

Market Segmentation

The global radioligand therapy market is segmented into indication, product, biomarker, end user, and company. Based on indication, the market is divided into prostate cancer, neuroendocrine tumor, and others. Based on product, the market is divided into lutathera, zytiga, xtandi, and xofigo. Based on a biomarker, the market is divided into prostate-specific membrane antigen, Ki 67 expression and grading, and cytochrome P450 17A1 inhibitor. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising cases of prostate cancer in the country.

Market Players

Novartis International, AG, Johnson & Johnson, Pfizer, Inc., Amneal Pharmaceuticals LLC., POINT Biopharma Global Inc, Fusion Pharmaceuticals Inc., Clovis Oncology, Inc., Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., Progenics Pharmaceuticals, and Bayer AG are some of the leading companies operating in the market.

Report Scope

In this report, global radioligand therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Radioligand Therapy Market, By Indication:

  • Prostate Cancer
  • Neuroendocrine Tumor
  • Others

Radioligand Therapy Market, By Product:

  • Lutathera
  • Zytiga
  • Xtandi
  • Xofigo

Radioligand Therapy Market, By Biomarker:

  • Prostate-Specific Membrane Antigen
  • Ki 67 Expression and Grading
  • Cytochrome P450 17A1 Inhibitor

Radioligand Therapy Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Radioligand Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Radioligand Therapy Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Radioligand Therapy Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Radioligand Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication (Prostate Cancer, Neuroendocrine Tumor, Others)
    • 7.2.2. By Product (Lutathera, Zytiga, Xtandi, Xofigo)
    • 7.2.3. By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
    • 7.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 7.2.5. By Region
    • 7.2.6. By Company (2021)
  • 7.3. Market Map

8. North America Radioligand Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product
    • 8.2.3. By Biomarker
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Radioligand Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Biomarker
        • 8.3.1.2.4. By End User
    • 8.3.2. Canada Radioligand Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Biomarker
        • 8.3.2.2.4. By End User
    • 8.3.3. Mexico Radioligand Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Biomarker
        • 8.3.3.2.4. By End User

9. Europe Radioligand Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product
    • 9.2.3. By Biomarker
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Radioligand Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Biomarker
        • 9.3.1.2.4. By End User
    • 9.3.2. Germany Radioligand Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Biomarker
        • 9.3.2.2.4. By End User
    • 9.3.3. United Kingdom Radioligand Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Biomarker
        • 9.3.3.2.4. By End User
    • 9.3.4. Italy Radioligand Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Product
        • 9.3.4.2.3. By Biomarker
        • 9.3.4.2.4. By End User
    • 9.3.5. Spain Radioligand Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Product
        • 9.3.5.2.3. By Biomarker
        • 9.3.5.2.4. By End User

10. Asia-Pacific Radioligand Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product
    • 10.2.3. By Biomarker
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Radioligand Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Biomarker
        • 10.3.1.2.4. By End User
    • 10.3.2. India Radioligand Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Biomarker
        • 10.3.2.2.4. By End User
    • 10.3.3. Japan Radioligand Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Biomarker
        • 10.3.3.2.4. By End User
    • 10.3.4. South Korea Radioligand Therapy Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Indication
        • 10.3.4.2.2. By Product
        • 10.3.4.2.3. By Biomarker
        • 10.3.4.2.4. By End User
    • 10.3.5. Australia Radioligand Therapy Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Indication
        • 10.3.5.2.2. By Product
        • 10.3.5.2.3. By Biomarker
        • 10.3.5.2.4. By End User

11. South America Radioligand Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Product
    • 11.2.3. By Biomarker
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Radioligand Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Product
        • 11.3.1.2.3. By Biomarker
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Radioligand Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Product
        • 11.3.2.2.3. By Biomarker
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Radioligand Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Product
        • 11.3.3.2.3. By Biomarker
        • 11.3.3.2.4. By End User

12. Middle East and Africa Radioligand Therapy Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Indication
    • 12.2.2. By Product
    • 12.2.3. By Biomarker
    • 12.2.4. By End User
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Radioligand Therapy Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Indication
        • 12.3.1.2.2. By Product
        • 12.3.1.2.3. By Biomarker
        • 12.3.1.2.4. By End User
    • 12.3.2. Saudi Arabia Radioligand Therapy Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Indication
        • 12.3.2.2.2. By Product
        • 12.3.2.2.3. By Biomarker
        • 12.3.2.2.4. By End User
    • 12.3.3. UAE Radioligand Therapy Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Indication
        • 12.3.3.2.2. By Product
        • 12.3.3.2.3. By Biomarker
        • 12.3.3.2.4. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

  • 15.1. Novartis International, AG
  • 15.2. Johnson & Johnson
  • 15.3. Pfizer, Inc.
  • 15.4. Amneal Pharmaceuticals LLC.
  • 15.5. POINT Biopharma Global Inc
  • 15.6. Fusion Pharmaceuticals Inc.
  • 15.7. Clovis Oncology, Inc.
  • 15.8. Telix Pharmaceuticals Limited
  • 15.9. Lantheus Holdings, Inc.
  • 15.10. Progenics Pharmaceuticals
  • 15.11. Bayer AG

16. Strategic Recommendations